(function(){var loadHandler=window['sl_{21FEF8D7-4385-4DEB-B34B-7A4BB675EF9A}'];loadHandler&&loadHandler(8, '<div id="spr0_15872f76"><div id="spr1_15872f76" class="kern slide"><img id="img7_15872f76" src="data/img8.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_15872f76" class="kern slide"><img id="img0_15872f76" src="data/img17.png" width="721.48" height="46.226" alt="" style="left:-0.439px;top:492.774px;"/><img id="img1_15872f76" src="data/img1.png" width="721.48" height="100.8" alt="" style="left:-0.439px;top:-1px;"/><div id="spr3_15872f76" style="left:657.715px;top:501.143px;"><img id="img2_15872f76" src="data/img3.png" width="56" height="36" alt="CHRC logo_with text.psd" style="left:-0.105px;top:-0.177px;"/></div><div id="spr4_15872f76" style="left:20.047px;top:17.674px;"><div style="width:0px;"><span id="txt0_15872f76" data-width="500.343750" style="left:90.765px;top:5.272px;"> ODYSSEY Outcomes Study Design</span></div></div><div id="svg2_15872f76" style="left:15.643px;top:101.997px;"><svg width="697" height="72" viewBox="0 0 697 72"><path fill="#451c6a" d="M0,0 h696.222 v71.875 h-696.222 Z"/></svg></div><div id="spr5_15872f76" style="left:15.643px;top:101.997px;"><div style="width:0px;"><span id="txt1_15872f76" class="nokern relpos" data-width="163.396637" style="left:203.989px;top:4.218px;">Post-ACS (4-52 weeks) patients</span><span id="txt2_15872f76" class="nokern relpos" style="left:203.984px;top:4.363px;">1</span><span id="txt3_15872f76" class="nokern relpos" data-width="120.653419" style="left:203.979px;top:4.218px;"> age ≥40 yrs (n~18,000)</span></div><div style="width:0px;"><span id="txt4_15872f76" class="nokern relpos" data-width="24.902626" style="left:156.799px;top:20.204px;">with </span><span id="txt5_15872f76" class="nokern relpos" data-width="363.461700" style="left:156.794px;top:20.165px;">LDL-C ≥1.81 mmol/L, or ApoB ≥ 0.8 g/L, or Non-HDL-C ≥ 2.59 mmol/L</span></div><div style="width:0px;"><span id="txt6_15872f76" class="nokern" data-width="673.744263" style="left:8.674px;top:36.208px;">despite high-intensity (or maximally tolerated) statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg/daily) x ≥2 wks ± other lipid-</span></div><div style="width:0px;"><span id="txt7_15872f76" class="nokern relpos" data-width="242.354767" style="left:225.239px;top:52.203px;">modifying therapy (e.g., ezetimibe, fenofibrate)</span><span id="txt8_15872f76" class="nokern relpos" style="left:225.234px;top:52.348px;">2</span></div></div><div id="spr6_15872f76" style="left:95.087px;top:176.733px;"><div id="svg3_15872f76" style="top:33.042px;"><svg width="266" height="66" viewBox="0 0 266 66"><path fill="#6b4487" d="M0,0 h265.222 v65.433 h-265.222 Z"/></svg></div><div id="spr7_15872f76" style="top:33.042px;"><div style="width:0px;"><span id="txt9_15872f76" class="nokern" data-width="242.250000" style="left:11.236px;top:4.157px;">Alirocumab 75 mg SC Q2wks x 2 months → 150 mg</span></div><div style="width:0px;"><span id="txt10_15872f76" class="nokern" data-width="146.548828" style="left:59.236px;top:18.557px;">SC Q2wks based upon Month 1</span></div><div style="width:0px;"><span id="txt11_15872f76" class="nokern relpos" data-width="92.970703" style="left:13.986px;top:32.957px;">LDL-C ≥ 1.3 mmol/L</span><span id="txt12_15872f76" class="nokern relpos" data-width="7.296875" style="left:13.981px;top:33.088px;">4  </span><span id="txt13_15872f76" class="nokern relpos" data-width="136.693359" style="left:13.976px;top:32.957px;">with dose titrated to maintain</span></div><div style="width:0px;"><span id="txt14_15872f76" class="nokern" data-width="189.187500" style="left:37.861px;top:47.357px;">LDL-C in the 0.6-1.3 mmol/L target range</span></div></div><div id="spr8_15872f76" style="left:129.913px;top:2.267px;"><img id="img3_15872f76" src="data/img21.png" width="141" height="30" alt=""/></div><div id="svg4_15872f76" style="left:310.444px;top:33.042px;"><svg width="190" height="25" viewBox="0 0 190 25"><path fill="#6b4487" d="M0,0 h189.556 v24.502 h-189.556 Z"/></svg></div><div id="spr9_15872f76" style="left:310.444px;top:33.042px;"><div style="width:0px;"><span id="txt15_15872f76" class="nokern" data-width="105.004425" style="left:42.215px;top:4.261px;">Placebo SC Q2wks</span></div></div><div id="spr10_15872f76" style="left:267.913px;top:2.267px;"><img id="img4_15872f76" src="data/img22.png" width="141" height="31" alt=""/></div><div id="svg5_15872f76" style="left:165.778px;top:11.708px;"><svg width="206" height="25" viewBox="0 0 206 25"><path fill="none" d="M0,0 h205.222 v24.502 h-205.222 Z"/></svg></div><div id="spr11_15872f76" style="left:165.778px;top:11.708px;"><div style="width:0px;"><span id="txt16_15872f76" class="nokern relpos" data-width="83.570274" style="left:58.611px;top:4.261px;">Randomization</span><span id="txt17_15872f76" class="nokern relpos" style="left:58.606px;top:4.416px;">3</span></div></div></div><div id="spr12_15872f76" style="left:34.643px;top:230.622px;"><div id="svg6_15872f76" style="top:74.042px;"><svg width="659" height="77" viewBox="0 0 659 77"><path fill="#935dbb" d="M0,0 h658.889 v76.197 h-658.889 Z"/></svg></div><div id="spr13_15872f76" style="top:74.042px;"><div style="width:0px;"><span id="txt18_15872f76" class="nokern" data-width="643.399475" style="left:7.632px;top:4.261px;">Primary Endpoint: Time to first CHD death/non-fatal MI/fatal and non-fatal ischemic stroke/unstable angina requiring</span></div><div style="width:0px;"><span id="txt19_15872f76" class="nokern" data-width="81.640022" style="left:288.567px;top:21.326px;">hospitalization</span></div><div style="width:0px;"><span id="txt20_15872f76" class="nokern" data-width="604.912415" style="left:26.757px;top:38.391px;">Follow-Up: Minimum 24 months or target number of events (~1600) → estimated 11.4% rate at 4 yrs, 15% risk</span></div><div style="width:0px;"><span id="txt21_15872f76" class="nokern" data-width="262.153473" style="left:198.257px;top:55.456px;">reduction; 90% power, 1-sided p=0.025, 1% lost</span></div></div><div id="spr14_15872f76" style="left:191.357px;top:49.378px;"><img id="img5_15872f76" src="data/img23.png" width="8" height="18" alt=""/></div><div id="spr15_15872f76" style="left:463.357px;top:3.378px;"><img id="img6_15872f76" src="data/img24.png" width="8" height="70" alt=""/></div></div><div id="spr16_15872f76" style="left:25.421px;top:394.105px;"><div style="width:0px;"><span id="txt22_15872f76" class="relpos" style="left:7.2px;top:4.288px;">1</span><span id="txt23_15872f76" class="relpos" data-width="585.943359" style="left:7.195px;top:4.157px;"> Elevated troponin or CK-MB or resting ECG changes + obstructive coronary disease (new/presumed new ischemia/infarction</span></div><div style="width:0px;"><span id="txt24_15872f76" data-width="457.189453" style="left:7.2px;top:18.557px;">by perfusion imaging, regional wall motion abnormality, coronary stenosis ≥70% by angiography)</span></div><div style="width:0px;"><span id="txt25_15872f76" class="relpos" data-width="5.472656" style="left:7.2px;top:33.088px;">2 </span><span id="txt26_15872f76" class="relpos" data-width="359.525391" style="left:7.195px;top:32.957px;">Key exclusion criteria: Uncontrolled hypertension; NYHA III-IV or LVEF&lt;25%;</span></div><div style="width:0px;"><span id="txt27_15872f76" data-width="329.208984" style="left:7.2px;top:47.357px;">prior hemorrhagic stroke; TG&gt;4.52 mmol/L; hepatitis; eGFR&lt;30 ml/min</span></div><div style="width:0px;"><span id="txt28_15872f76" class="relpos" data-width="5.472656" style="left:7.2px;top:61.888px;">2 </span><span id="txt29_15872f76" class="relpos" data-width="455.830078" style="left:7.195px;top:61.757px;">Following ≥2 wk (+ 5 days) run-in period with placebo (1 mL volume in an autoinjector) SC Q2wks</span></div><div style="width:0px;"><span id="txt30_15872f76" class="relpos" style="left:7.2px;top:76.288px;">3</span><span id="txt31_15872f76" class="relpos" data-width="178.798828" style="left:7.195px;top:76.157px;"> Titration downwards for very low LDL</span></div></div><div id="spr17_15872f76" style="left:19.805px;top:512.807px;"><div style="width:0px;"><span id="txt32_15872f76" class="nokern" data-width="157.548340" style="left:9.816px;top:6.712px;">Schwartz et al Am Heart J 2014;168:682-689.e1</span></div><div style="width:0px;"><span id="txt33_15872f76" class="nokern" data-width="157.548340" style="left:9.321px;top:6.217px;">Schwartz et al Am Heart J 2014;168:682-689.e1</span></div></div><div id="spr18_15872f76" style="left:19.805px;top:512.807px;"><div style="width:0px;"><span id="txt34_15872f76" class="nokern" data-width="157.548340" style="left:7.695px;top:4.591px;">Schwartz et al Am Heart J 2014;168:682-689.e1</span></div><div style="width:0px;"><span id="txt35_15872f76" class="nokern" data-width="157.548340" style="left:7.2px;top:4.096px;">Schwartz et al Am Heart J 2014;168:682-689.e1</span></div></div></div></div>');})();